All In Biotech

Drug Trial Radar · NCT00153816

Vitamin D/Calcium Polyp Prevention Study

Last checked: Nov 20, 2026Latest source record: Mar 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,813 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,813

Actual

Start

Jul 2004

Primary completion

Oct 2013

Study completion Jun 2016

Sponsor

Lead sponsor
Dartmouth-Hitchcock Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 45 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Extensive experimental and observational data suggest that intake of calcium and of vitamin D exert protective effects on colorectal neoplasia. Building on their previous work, the investigators will investigate the chemopreventive effect of vitamin D in the large bowel, to study whether calcium with vitamin D is more effective than calcium alone, and to confirm their positive finding regarding calcium. The goal of this study is the development of chemopreventive combinations that will reduce risk of colorectal neoplasia sufficiently to permit the lengthening of surveillance intervals in most patients and to clarify important issues regarding the mechanisms of colorectal carcinogenesis and chemoprevention.

Conditions

  • Colorectal Cancer
  • Polyps
  • Adenomas

Interventions

  • Calcium CarbonateDrug

    3 gm/daily; 1200 mg elemental calcium/daily; two tablets per day; 600 mg elemental calcium/tablet

  • Vitamin D3Drug

    1000 IU/daily; two tablets per day; 500 IU per tablet

  • placeboDrug

    placebo; two tablets per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Colorectal AdenomasTime frame: 1 to 10 years

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Southern California

    Los Angeles, California

  • University of Colorado

    Denver, Colorado

  • Emory University

    Atlanta, Georgia

  • University of Iowa

    Iowa City, Iowa

  • University of Minnesota

    Minneapolis, Minnesota

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire

  • University of North Carolina

    Chapel Hill, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • University of South Carolina

    Columbia, South Carolina

  • University of Texas

    Houston, Texas

  • University of Puerto Rico

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.